Deininger Lab
The Deininger Lab has a long-standing interest in the biology and therapy of leukemia, specifically chronic myeloproliferative neoplasms (CMPN), including chronic myeloid leukemia (CML) and Philadelphia chromosome (Ph)-negative CMPN.
As a physician, Deininger's expertise is in the treatment of leukemia. As a scientist, his research program focuses on the biology of myeloproliferative neoplasms and the development of molecularly targeted therapies. The lab is especially interested in understanding the molecular mechanisms of resistance to tyrosine kinase inhibitors such as imatinib, a drug used to treat chronic myeloid leukemia and some other types of cancer.
Michael W. Deininger, MD, PhD
Chief, Division of Hematology and Hematologic Malignancies
M. M. Wintrobe Professor of Medicine
Huntsman Cancer Institute
The University of Utah
Salt Lake City, Utah
